Platelet Function Inhibitors

References
1 Mustard JF, Packham MA, Kinlough-Rathbone RL. Mechanisms in thrombosis: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (Eds) Churchill Livingstone; London: 1981. pp 503-526
2 Fuster V, Chesebro JH. Antithrombotic therapy: Role of platelet- inhibitor drugs. I. Current concepts of thrombogenesis: role of platelets. Mayo Clinic Proc 1981; 56: 102-112
3 Baumgartner HR, Muggli R, Tschopp TB, Turitto VT. Platelet adhesion, release and aggregation in flowing blood: effects of surface properties and platelet function. Thromb Haemostas 1976; 35: 124-138
4 Groves HM, Kinlough-Rathbone RL, Richardson M, Jorgensen L, Moore S, Mustard JF. Thrombin generation and fibrin formation following injury to rabbit neointima: studies of vessel wall reactivity and platelet survival. Lab Invest 1982; 46: 605-612
5 Packham MA, Kinlough-Rathbone RL, Reimers H-J, Scott S, Mustard JF. Mechanisms of platelet aggregation independent of adenosine diphosphate: Prostaglandins in Hematology. Silver MJ, Smith JB, Kocsis JJ. (Eds) Spectrum Publications; New York: 1977. pp 247-276
6 Vargaftig BB, Chignard M, Benveniste J. Present concepts on the mechanisms of platelet aggregation. Biochem Pharmacol 1981; 30: 263-271
7 Charo IF, Feinman RD, Detwiler TC. Interrelationships of platelet aggregation and secretion. J Clin Invest 1977; 60: 866-873
8 Weiss HJ. Platelets. Pathophysiology and antiplatelet drug therapy. Alan R Liss; New York: 1982. pp 1-165
9 Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation: Methods of Hematology. Measurements of Platelet Function. Harker LA, Zimmerman TS. (Eds) Churchill Livingstone; New York: (in press)
10 Packham MA, Mustard JF. Normal and abnormal platelet activity: Blood Platelet Function: Hemodynamics and Medicinal Chemistry. Lasslo A. (Ed) Elsevier North Holland; New York: (in press)
11 Kinlough-Rathbone RL, Packham MA, Reimers H-J, Cazenave JP, Mustard JF. Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23187. J Lab Clin Med 1977; 90: 707-719
12 Kinlough-Rathbone RL, Cazenave J-P, Packham MA, Mustard JF. Effect of inhibitors of the arachidonate pathway on the release of granule contents from rabbit platelets adherent to collagen. Lab Invest 1980; 42: 28-34
13 Holmsen H. Platelet secretion (release reaction) - mechanism and pharmacology. Adv Pharmacol Therapeut 1978; 4: 97-109
14 Feinstein MB, Walenga R. The role of calcium in platelet activation: Biochemistry of the Acute Allergic Reactions. Becker EL, Simon AS, Austen KF. (Eds) Alan R Liss; New York: 1981. pp 279-293
15 Gerrard JM, White JG. Prostaglandins and thromboxanes: “Middlemen” modulating platelet function in hemostasis and thrombosis: Progress in Hemostasis and Thrombosis. Spaet TH. (Ed) Grune & Stratton; New York: 1978. 4 87-125
16 Haslam RJ, Davidson MM L, Davies T, Lynham JA, McClenaghan MD. Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucl Res 1978; 9: 533-552
17 Cazenave J-P, Dejana E, Kinlough-Rathbone RL, Richardson M, Packham MA, Mustard JF. Prostaglandins I₂ and E₁ reduce rabbit and human platelet adherence without inhibiting serotonin release from adherent platelets. Thromb Res 1979; 15: 273-279
18 Nachman RL, Leung LL K. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest 1982; 69: 263-269
19 Packham MA, Mustard JF. Pharmacology of platelet-affecting drugs. Circulation 1980; 62 Suppl (Suppl. 05) 26-41
20 Fuster V, Chesebro JH. Antithrombotic therapy: role of platelet inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs. Mayo Clin Proc 1981; 56: 185-195
21 Rao GH R, Reddy KR, White JG. The influence of epinephrine on prostacyclin (PGI₂) induced dissociation of ADP aggregated platelets. Prostaglandins Med 1980; 4: 385-397
22 Kinlough-Rathbone RL, Mustard JF, Perry DW, Dejana E, Cazenave J-P, Packham MA, Harfenist EJ. Factors influencing the deaggregation of human and rabbit platelets. Thromb Haemostas 1983; 49: 162-167
23 Holmsen H. Platelet secretion: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. (Eds) J B Lippincott; Philadelphia: 1982: 390-403
24 Holmsen H. Mechanisms of platelet secretion: Platelets: Cellular Response Mechanisms and their Biological Significance. Rotman A, Meyer FA, Gitler C, Silberberg A. (Eds) John Wiley & Son; New York: 1980. pp 249-263
25 Vickers JD, Kinlough-Rathbone RL, Mustard JF. Changes in phosphatidylinositol-4,5-bisphosphate 10 seconds after stimulation of washed rabbit platelets with ADP. Blood 1982; 60: 1247-1250
26 Rittenhouse-Simmons S. Production of diglyceride from phosphatidylinositol in activated human platelets. J Clin Invest 1979; 63: 580-587
27 Lapetina EG, Billah MM, Cuatrecasas P. The initial action of thrombin on platelets. Conversion of phosphatidylinositol to phosphatidic acid preceding the production of arachidonic acid J Biol Chem 1981; 256: 5037-5040
28 Michell RH, Kirk CJ. The unknown meaning of receptor-stimulated inositol lipid metabolism. TIPS 1982; 3: 140-141
29 Imai A, Yano K, Kameyama Y, Nozawa Y. Evidence for predominance of phospholipase A₂ in release of arachidonic acid in thrombin-activated platelets. Phosphatidylinositol-specific phospholipase C may play a minor role in arachidonate liberation Jpn J Exp Med 1982; 52: 99-105
30 Kishimoto A, Takai Y, Mori T, Kikkawa U, Nishizuka A. Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidyl-inositol turnover. J Biol Chem 1980; 255: 2273-2276
31 Gerrard JM, Peterson DA, White JG. Calcium mobilization: Platelets in Biology and Pathology 2. Gordon JL. (Ed) Elsevier/ North Holland; Oxford: 1981. pp 407-436
32 Gerrard JM, Kindom SE, Peterson DA, Peller J, Krantz KE, White JG. Lysophosphatidic acids. Influence on platelet aggregation and intracellular calcium flux Am J Pathol 1979; 96: 423-438
33 Lapetina EG. Regulation of arachidonic acid production: role of phospholipases C and A₂ . TIPS 1982; 3: 116-119
34 Winocour PD, Kinlough-Rathbone RL, Mustard JF. The effect of the phospholipase inhibitor mepacrine on platelet aggregation, the platelet release reaction and fibrinogen binding to the platelet surface. Thromb Haemostas 1981; 45: 257-262
35 Bell RL, Kennedy DA, Stanford N, Majerus PW. Diglyceride lipase: A pathway for arachidonate release from human platelets. Proc Natl Acad Sci USA 1979; 76: 3238-3241
36 Chap H, Mauco G, Perret B, Plantavid M, Laffont F, Simon MF, Douste-Blazy L. Studies on topological distribution of arachidonic acid replacement in platelet phospholipids and on enzymes involved in the phospholipid effect accompanying platelet activation. Agents Actions 1981; 11: 538-540
37 Broeckman MJ, Ward JW, Marcus AJ. Fatty acid composition of phosphatidylinositol and phosphatidic acid in stimulated platelets. Persistence of arachidonyl-stearyl structure J Biol Chem 1981; 256: 8271-8274
38 Rittenhouse-Simmons S. Changes in arachidonate-containing complex lipid during platelet stimulation. Thromb Haemostas 1981; 46: 321 (Abstr.)
39 Seamon KB, Daly JW. Forskolin: a unique diterpene activator of cyclic AMP-generating systems. J Cyclic Nucleotide Res 1981; 7: 201-224
40 Agarwal KC, Parks Jr RE. Inhibition of human platelet aggregation by forskolin, prostaglandin E₁ and adenosine analogs. Fed Proc 1982; 41: 701
41 Siegl AM, Daly JW, Smith JB. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. Mol Pharmacol 1982; 21: 680-687
42 Insel PA, Stengel D, Ferry N, Hanoune J. Regulation of adenylate cyclase of human platelet membranes by forskolin. J Biol Chem 1982; 257: 7485-7490
43 Fleming JS, Buyniski JB. A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb Res 1979; 15: 373-388
44 Smith JB. Effect of thromboxane synthetase inhibitors on platelet function: Enhancement by inhibition of phosphodiesterase. Thromb Res 1982; 28: 477-485
45 Beretz A, Cazenave J-P, Anton R. Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: Structure-activity relationships. Agents Actions 1982; 12: 382-387
46 Beretz A, Stierlé A, Anton R, Cazenave J-P. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin. Biochem Pharmacol 1982; 31: 3597-3600
47 Hidaka H, Hayashi H, Kohri H, Kimura H, Hosokawa T, Igawa T, Saitoh Y. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther 1979; 211: 26-30
48 Coppe D, Sobel M, Seamans L, Levin F, Salzman EW. Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981; 81: 274-278
49 Turney JH, Dodd NJ, Weston MJ. Prostacyclin in extracorporeal circulations. Lancet 1981; 1: 1101
50 Groves HM, Kinlough-Rathbone RL, Cazenave J-P, Dejana E, Richardson M, Mustard JF. Effect of dipyridamole and prostacyclin on rabbit platelet adherence in vitro and vivo. J Lab Clin Med 1982; 99: 548-558
51 Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley WT, Frye RL, Holmes Jr DR, Vlietstra RE, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Schaff HV, Danielson GK. A platelet-inhibitor-drug trial in coronary-artery bypass operations. N Engl J Med 1982; 307: 73-78
52 Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-319
53 Masotti G, Galanti G, Poggesi L, Abbate R, Neri SerneriG. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet 1979; 2: 1213-1216
54 Ellis EF, Wright KF, Jones PS, Richardson DW, Ellis CK. Effect of oral aspirin dose on platelet aggregation and vascular prostacyclin (PGI₂) synthesis in humans and rabbits. J Cardiovasc Pharmacol 1980; 2: 387-397
55 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327
56 Packham MA, Mustard JF. Pharmacology of antiplatelet agents and their role in coronary disease: Myocardial Infarction and Cardiac Death. Margulies E. (Ed) Academic Press; New York: 1983. pp 93-142
57 Ah M, McDonald JW D. Interference by sulfinpyrazone and salicylate of aspirin inhibition of platelet cyclooxygenase activity. Prostaglandins Med 1979; 3: 327-332
58 Dejana E, Cerletti C, de Castellarnau C, Livio M, Galletti F, Latini R, de Gaetano G. Salicylate-aspirin interaction in the rat. Evidence that salicylate accumulating during aspirin administration may protect vascular prostacyclin from aspirin-induced inhibition J Clin Invest 1981; 68: 1108-1112
59 Vargaftig BB. The inhibition of cyclo-oxygenase of rabbit platelets by aspirin is prevented by salicylic acid and by phenanthrolines. Eur J Pharmacol 1978; 50: 231-241
60 Cerletti C, Livio M, de Gaetano G. Non-steroidal anti-inflammatory drugs react with two sites on platelet cyclo-oxygenase. Evidence from “in vivo” drug interaction studies in rats Biochim Biophys Acta 1981; 714: 122-128
61 Peterson DA, Gerrard JM, Rao GH R, Mills EL, White JG. Interaction of arachidonic acid and heme iron in the synthesis of prostaglandins. Adv Prostaglandin Thrombox Res 1980; 6: 157-161
62 Peterson DA, Gerrard JM, Rao GH R, White JG. Salicylic acid inhibition of the irreversible effect of acetylsalicylic acid on prostaglandin synthetase may be due to competition for the enzyme cationic binding site. Prostaglandins Med 1981; 6: 161-164
63 Livio M, Delmaschio A, Cerletti C, de Gaetano G. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 1982; 23: 787-796
64 Butler KD, Dieterle W, Maguire ED, Pay GF, Wallis RB, White AM. Sustained effects of sulfinpyrazone: Cardiovascular Actions of Sulfinpyrazone: Basic and Clinical Research. McGregor M, Mustard JF, Oliver MF, Sherry S. (Eds) Symposia Specialists; Miami, Florida: 1980. pp 19-35
65 Cazenave J-P, Kinlough-Rathbone RL, Packham MA, Mustard JF. The effect of acetylsalicylic acid and indomethacin on rabbit platelet adherence to collagen and the subendothelium in the presence of a low or high hematocrit. Thromb Res 1978; 13: 971-981
66 Gorman RR, Fitzpatrick FA, Miller OV. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH₂ . Biochem Biophys Res Commun 1977; 79: 305-313
67 Needleman P, Raz A, Ferrendelli JA, Minkes M. Application of imidazole as a selective inhibitor of thromboxane synthetase in human platelets. Proc Natl Acad Sci USA 1977; 74: 1716-1720
68 Fitzpatrick FA, Gorman R, Bundy G, Honohan T, McGuire J, Sun F. 9,11-iminoepoxyprosta-5,13-dienoic acid is a selective thromboxane A₂ synthetase inhibitor. Biochim Biophys Acta 1979; 573: 238-244
69 Allan G, Eakins KE, Kulkarni PS, Levi R. Inhibition of thromboxane A₂ biosynthesis in human platelets by burimamide. Br J Pharmacol 1980; 71: 157-164
70 Smith JB, Jubiz W. OKY-1581: a selective inhibitor of thromboxane synthesis in vivo and in vitro. Prostaglandins 1981; 22: 353-363
71 Grimm LJ, Knapp DR, Senator D, Halushka PV. Inhibition of platelet thromboxane synthesis by 7-(l-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation. Thromb Res 1981; 24: 307-317
72 Randall MJ, Parry MJ, Hawkeswood E, Cross PE, Dickinson RP. UK-37,248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. Thromb Res 1981; 23: 145-162
73 Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry MJ. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res 1980; 20: 219-230
74 Bertele V, Cerletti C, Schieppati A, Di Minno G, de Gaetano G. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet 1981; 1: 1057-1058
75 Bertele V, Falanga A, Roncaglioni MC, Cerletti C, de Gaetano G. Thromboxane synthetase inhibition results in increased platelet sensitivity to prostacyclin. Thromb Haemostas 1982; 47: 294
76 Vermylen J, Defreyn G, Carreras LO, Machin SJ, van Schaeren J, Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet 1981; 1: 1073-1075
77 Defreyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood toward prostacyclin and prostaglandin E₂ . Thromb Res 1982; 26: 389-400
78 Tremoli E, Maderna P, Colli S, Agradi E, Petroni A, Paoletti R. GYKI 14,451, a synthetic tripeptide inhibitor of thrombin: activity on platelet aggregation and arachidonic acid metabolism. Pharmacol Res Commun 1981; 13: 339-349
79 Collen D, Matsuo O, Stassen JM, Kettner C, Shaw E. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med 1982; 99: 76-83
80 Barnathan ES, Addonizio VP, Shattil SJ. Interaction of verapamil with human platelet α-adrenergic receptors. Am J Physiol 1982; 242: H19-H23
81 Rossi EC, Louis G, Zeller EA. Structure activity relationships between catecholamines and the α-adrenergic receptor responsible for the aggregation of human platelets by epinephrine. J Lab Clin Med 1979; 93: 286-294
82 Rao GH R, Johnson GJ, White JG. Influence of epinephrine on the aggregation response of aspirin-treated platelets. Prostaglandins Med 1980; 5: 45-58
83 Rao GH R, Gerrard JM, Witkop CJ, White JG. Platelet aggregation independent of ADP release or prostaglandin synthesis in patients with Hermansky-Pudlak syndrome. Prostaglandins Med 1981; 6: 459-472
84 Rao GH R, Reddy KR, White JG. Modification of human platelet response to sodium arachidonate by membrane modulation. Prostaglandins Med 1981; 6: 75-90
85 De Clerck F, David J-L, Janssen PA J. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketan- serin (R 41 468), a selective 5-HT₂-receptor antagonist. Agents Actions 1982; 12: 388-397
86 Aledort LM. Platelet aggregation: The Circulating Platelet. Johnson SA. (Ed) Academic Press; New York: 1971. pp 259-281
87 Davies T, Davidson MM, McClenaghan MD, Say A, Haslam RJ. Factors affecting platelet cyclic GMP levels during aggregation induced by collagen and by arachidonic acid. Thromb Res 1976; 9: 387-405
88 Chignard M, Wal F, Lefort J, Vargaftig BB. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-Acether) in the guinea-pig. Eur J Pharmacol 1982; 78: 71-79
89 Gasic GJ, Koch PA G, Hsu B, Gasic TB, Niewiarowski S. Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation and fibrinolysis, and possible significance for metastases. Z Krebsforsch 1976; 86: 263-277
90 Jamieson GA, Scipio AR. (Eds) Interactions of platelets and tumor cells. Alan R Liss; New York: Prog Clin Biol Res. 1982. 89 1-523
91 Donati MB, Rotillio D, Delaini F, Giavazzi R, Mantovani A, Poggi A. Animal models for the study of platelet-tumor cell interactions: Interaction of Platelets and Tumor Cells. Jamieson GA, Scipio AR. (Eds) Alan R Liss; New York: Prog Clin Biol Res. 1982. 89 159-176
92 Langer BG, Leung LL K, Gonnella PA, Nachmias VT, Nachman RL, Pepe FA. α-Actinin and membrane glycoprotein Ilia are different proteins in human blood platelets. Proc Natl Acad Sci USA 1982; 79: 432-435
93 Niederman R, Pollard TD. Human platelet myosin. II. In vitro assembly and structure of myosin filaments. J Cell Biol 1975; 67: 72-92
94 Haslam RJ, Davidson MM, McClenaghan MD. Cytochalasin B, the blood platelet release reaction and cyclic GMP. Nature 1975; 253: 455-456
95 Kirkpatrick JP, Mclntire LV, Moake JL, Cimo PL. Differential effects of cytochalasin B on platelet release, aggregation and contractility: Evidence against a contractile mechanism for the release of platelet granular contents. Thromb Haemostas 1979; 42: 1483-1489
96 Peerschke EI, Zucker MB. Relationship of ADP-induced fibrinogen binding to platelet shape change and aggregation elucidated by use of colchicine and cytochalasin B. Thromb Haemostas 1980; 43: 58-60
97 Kuntamukkula MS, Moake JL, Mclntire LV, Cimo PL. Effects of colchicine and vinblastine on platelet contractility and release. Thromb Res 1982; 26: 329-339
98 Kindness G, Williamson FB, Long WF. Inhibitory effect of trifluoperazine on aggregation of human platelets. Thromb Res 1980; 17: 549-554
99 White II GC, Raynor ST. The effects of trifluoperazine, an inhibitor of calmodulin, on platelet function. Thromb Res 1980; 18: 279-284
100 Rao GH R, Reddy KR, White JG. Influence of trifluoperazine on platelet aggregation and disaggregation. Prostaglandins Med 1980; 5: 221-234
101 Mustard JF, Packham MA. Platelets, thrombosis and drugs: Cardiovascular Drugs. Vol. 3. Antithrombotic Drugs. Avery GS. (Ed) Adis Press; New York: 1978. 3 1-83
102 Lips JP M, Sixma JJ, Schiphorst ME. The effect of ticlopidine administration to humans on the binding of adenosine diphosphate to blood platelets. Thromb Res 1980; 17: 19-27
103 Kirstein P, Jogestrand T, Johnsson H, Olsson AG. Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis. Atherosclerosis 1980; 36: 471-480
104 Conard J, Lecrubier C, Scarabin PY, Horellou MH, Samama M, Bousser MG. Effects of long term administration of ticlopidine on platelet function and hemostatic variables. Thromb Res 1980; 20: 143-148
105 Aukland A, Hurlow RA, George AJ, Stuart J. Platelet inhibition with ticlopidine in atherosclerotic intermittent claudication. J Clin Pathol 1982; 35: 740-743
106 Fiskerstrand C, Thompson I, Burnett E, Williams P, Anderton JL. Assessment of the effect of ticlopidine in arteriovenous access for haemodialysis. Haemostasis 1982; 12: 104
107 Aubert O, Bernat A, Ferrand JC, Maffrand JP, Szygenda E, Tuong C, Vallee E. Pharmacological profile of PCR 3787: a metabolite of ticlopidine. Haemostasis 1982; 12: 137
108 Cattaneo M, Kinlough-Rathbone RL, Winocour PD, Packham MA, Mustard JF. Ticlopidine prolongs shortened platelet survival by inhibiting clearance of altered platelets. Fed Proc 1982; 41: 701
109 Kornecki E, Feinberg H. Pyridoxal phosphate inhibition of platelet function. Am J Physiol 1980; 238: H54-H60
110 Lam SC-T, Harfenist EJ, Packham MA, Mustard JF. Investigation of possible mechanisms of pyridoxal 5’-phosphate inhibition of platelet reactions. Thromb Res 1980; 20: 633-645
111 Krishnamurthi S, Westwick J, Kakkar VV. Effect of pyridoxal 5’- phosphate (PALP) on human platelet aggregation, dense granule release and thromboxane B₂ generation - role of Schiff base formation. Thromb Haemostas 1982; 48: 136-141
112 Shattil SJ, McDonough M, Burch JW. Inhibition of platelet phospholipid methylation during platelet secretion. Blood 1981; 57: 537-544
113 Randon J, Lecompte T, Chignard M, Siess W, Marlas G, Dray F, Vargaftig BB. Dissociation of platelet aggregation from transmethylation of their membrane phospholipids. Nature 1981; 293: 660-662
114 Lecompte T, Randon J, Chignard M, Vargaftig BB, Dray F. Interference of transmethylation inhibitors with thromboxane synthesis in rat platelets. Biochem Biophys Res Commun 1982; 106: 566-573
115 Baumgartner HR, Born GV R. The relation between the 5- hydroxytryptamine content and aggregation of rabbit platelets. J Physiol 1969; 201: 397-408
116 Hallam TJ, Scrutton MC, Wallis RB. Responses of rabbit platelets to adrenaline induced by other agonists. Thromb Res 1981; 21: 413-424
117 Holmes IB. Potentiating effect of adrenaline on adenosine diphosphate-induced reduction in rabbit circulating platelet count: inhibition by dihydroergotoxine. Thromb Haemostas 1979; 42: 641-648
118 Doni MG, Aragno R. Effect of catecholamines on ADP aggregation of rat platelets in vivo. Experientia 1977; 33: 1331-1332
119 Markwardt F, Glusa E, Barthel W. Influence of dihydroergotoxine on platelet aggregation in rabbits. Thromb Res 1977; 10: 783-789
120 Huang EM, Detwiler TC. Characteristics of the synergistic actions of platelet agonists. Blood 1981; 57: 685-691
121 Kinlough-Rathbone RL, Packham MA, Mustard JF. Synergism between platelet aggregating agents: the role of the arachidonate pathway. Thromb Res 1977; 11: 567-580
122 Groves HM, Kinlough-Rathbone RL, Mustard JF. Personal communication.
123 Kallio V, Hamalainen H, Hakkila J, Luurila OJ. Reduction in sudden deaths by a multifactorial intervention programme after acute myocardial infarction. Lancet 1979; 2: 1091-1094
124 Hjermann I, Byre KV, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report of the Oslo Study Group of a randomised trial in healthy men Lancet 1981; 2: 1303-1313